CV Therapeutics to Announce 2004 First Quarter Financial Results on Friday, April 30, 2004
April 22 2004 - 6:00PM
PR Newswire (US)
CV Therapeutics to Announce 2004 First Quarter Financial Results on
Friday, April 30, 2004 PALO ALTO, Calif., April 22
/PRNewswire-FirstCall/ -- CV Therapeutics, Inc. today announced
that it will release first quarter financial results for 2004
before the market opens on Friday, April 30, 2004. Company
management will webcast a conference call at 8:30 a.m. EDT, 5:30
a.m. PDT, on the company's website. To access the live webcast,
please log on to the company's website at http://www.cvt.com/ and
go to the Investor Information section. Alternatively, domestic
callers may participate in the conference call by dialing
888-370-6121, and international callers may participate in the
conference call by dialing 706-679-7163. Webcast and telephone
replays of the conference call will be available approximately two
hours after the completion of the call through Friday, May 7, 2004.
Domestic callers can access the replay by dialing 800-642-1687, and
international callers can access the replay by dialing
706-645-9291; the PIN access number is 6681883. About CV
Therapeutics CV Therapeutics, Inc., headquartered in Palo Alto,
California, is a biopharmaceutical company focused on applying
molecular cardiology to the discovery, development and
commercialization of novel, small molecule drugs for the treatment
of cardiovascular diseases. CV Therapeutics currently has four
compounds in clinical development. Applications for the approval of
ranolazine for the treatment of chronic angina have been submitted
to the United States Food and Drug Administration (FDA) and the
European Agency for the Evaluation of Medicinal Products (EMEA).
Regadenoson, a selective A2A-adenosine receptor agonist, is being
developed for potential use as a pharmacologic stress agent in
cardiac perfusion imaging studies. Tecadenoson, an A1-adenosine
receptor agonist, is being developed for the potential reduction of
rapid heart rate during atrial arrhythmias. Adentri(TM), an
A1-adenosine receptor antagonist for the potential treatment of
congestive heart failure, is licensed to Biogen, Inc. (now Biogen
Idec Inc.). For more information, please visit CV Therapeutics'
website at http://www.cvt.com/. CV Therapeutics is a
development-stage company. None of the company's products have been
approved for marketing by the FDA, the EMEA or any other foreign
regulatory authorities. Any products of the company discussed here
are currently under investigation in clinical trials subject to
United States Investigational New Drug applications, and as
applicable, appropriate clinical trial applications to regulatory
authorities outside the United States. DATASOURCE: CV Therapeutics,
Inc. CONTACT: investors, Dan Spiegelman, SVP & Chief Financial
Officer, +1-650-384-8509, or Christopher Chai, Treasurer &
Executive Director, Investor Relations, +1-650-384-8560, or media,
John Bluth, Senior Director, Corporate Communications,
+1-650-384-8850, all of CV Therapeutics, Inc. Web site:
http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Oct 2023 to Oct 2024